Clinical Trial

EGCG for Hepatocellular Carcinoma Chemoprevention

Study acronym: CATCH-B
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-08-27; most recent amendment 2025-08-28.
Status change: Not Yet Recruiting → Recruiting 2024-08-07
Trial Details
NCT Number NCT06015022
Lead Sponsor University of Texas Southwestern Medical Center
Conditions Cirrhosis, Liver
Enrollment 60 participants
Start Date 2024-09-01
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-05